Expedition Therapeutics is a biotechnology company focused on developing innovative therapies for serious inflammatory and respiratory diseases. Their lead program, EXPD-101, is a next-generation DPP1 inhibitor with the potential to be a first-in-class treatment for chronic obstructive pulmonary disease (COPD) and other neutrophil-driven diseases. The company leverages deep expertise in translational science and clinical development, aiming to improve patient outcomes through cutting-edge therapeutic solutions.
Leadership & Board
Current Number of Employees18
Current LinkedIn Followers3,770
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$280M
Total Amount Raised$280M
Total Funding Rounds2
Total Funding Rounds2
Latest Funding Amount$115M
Latest Funding Amount$115M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
Expedition Therapeutics had 18 employees as of October 5, 2026. The number of employees increased by 0 (0.00%) week-over-week.
18Latest Employee Count
0(0.00%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
Expedition Therapeutics had 3,770 followers as of October 5, 2026. The number of followers increased by 49 (1.32%) week-over-week.
3,770Latest Followers Count
49(1.32%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.